DNAH8 and cancer: While Hsp90 dysregulation is a hallmark of numerous diseases, ranging from cancer to neurodegeneration, traditional inhibitors targeting its highly conserved ATPase site have largely failed in the clinic due to off-target toxicity and compensatory stress responses.